Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of a recombinant measles HIV-1 subtype C vaccine.
Stebbings R, Li B, Lorin C, Koutsoukos M, Février M, Mee ET, Page M, Almond N, Tangy F, Voss G. Stebbings R, et al. Among authors: voss g. Vaccine. 2013 Dec 9;31(51):6079-86. doi: 10.1016/j.vaccine.2013.09.072. Epub 2013 Oct 24. Vaccine. 2013. PMID: 24161574 Free article.
Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.
Page M, Stebbings R, Berry N, Hull R, Ferguson D, Davis L, Duffy L, Elsley W, Hall J, Ham C, Hassall M, Li B, Mee ET, Quartey-Papafio R, Rose NJ, Mathy N, Voss G, Stott EJ, Almond N. Page M, et al. Among authors: voss g. Retrovirology. 2012 Jul 16;9:56. doi: 10.1186/1742-4690-9-56. Retrovirology. 2012. PMID: 22799593 Free PMC article.
Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
Stebbings R, Février M, Li B, Lorin C, Koutsoukos M, Mee E, Rose N, Hall J, Page M, Almond N, Voss G, Tangy F. Stebbings R, et al. Among authors: voss g. PLoS One. 2012;7(11):e50397. doi: 10.1371/journal.pone.0050397. Epub 2012 Nov 30. PLoS One. 2012. PMID: 23226275 Free PMC article.
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepapeliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T; NIAID HIV Vaccine Trials Network. Goepfert PA, et al. Among authors: voss g. Vaccine. 2007 Jan 5;25(3):510-8. doi: 10.1016/j.vaccine.2006.07.050. Epub 2006 Aug 10. Vaccine. 2007. PMID: 17049679 Clinical Trial.
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
Leroux-Roels I, Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P, Cohen K, Altfeld M, Vandepapelière P, Pedneault L, McNally L, Leroux-Roels G, Voss G. Leroux-Roels I, et al. Among authors: voss g. Vaccine. 2010 Oct 8;28(43):7016-24. doi: 10.1016/j.vaccine.2010.08.035. Epub 2010 Aug 20. Vaccine. 2010. PMID: 20728522 Clinical Trial.
Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ. Cranage MP, et al. Among authors: voss g. Vaccine. 2011 Feb 4;29(7):1421-30. doi: 10.1016/j.vaccine.2010.12.034. Epub 2010 Dec 25. Vaccine. 2011. PMID: 21187177 Free PMC article.
Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques.
Lorin C, Segal L, Mols J, Morelle D, Bourguignon P, Rovira O, Mettens P, Silvano J, Dumey N, Le Goff F, Koutsoukos M, Voss G, Tangy F. Lorin C, et al. Among authors: voss g. Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec;385(12):1211-25. doi: 10.1007/s00210-012-0793-4. Epub 2012 Sep 16. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22983013 Free PMC article.
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
Harrer T, Plettenberg A, Arastéh K, Van Lunzen J, Fätkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G. Harrer T, et al. Among authors: voss g. Vaccine. 2014 May 7;32(22):2657-65. doi: 10.1016/j.vaccine.2013.10.030. Epub 2013 Oct 19. Vaccine. 2014. PMID: 24144472 Free article. Clinical Trial.
Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C, Vanloubbeeck Y, Baudart S, Ska M, Bayat B, Brauers G, Clarinval G, Donner MN, Marchand M, Koutsoukos M, Mettens P, Cohen J, Voss G. Lorin C, et al. Among authors: voss g. PLoS One. 2015 Apr 9;10(4):e0122835. doi: 10.1371/journal.pone.0122835. eCollection 2015. PLoS One. 2015. PMID: 25856308 Free PMC article.
An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, Collard A, Demoitié MA, Voss G, Leroux-Roels G, McNally L. Van Braeckel E, et al. Among authors: voss g. Clin Infect Dis. 2011 Feb 15;52(4):522-31. doi: 10.1093/cid/ciq160. Epub 2011 Jan 5. Clin Infect Dis. 2011. PMID: 21208909 Free PMC article. Clinical Trial.
258 results